Synopsis
Synopsis
0
NDC API
0
VMF
0
FDA Orange Book
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 182349-12-8
2. Rupatadin Fumarate
3. Rupafin
4. Ur-12592 Fumarate
5. Rupatadine (fumarate)
6. Alergoliber
7. Rinialer
8. Xj6ot32m93
9. 182349-12-8 (fumarate)
10. Rupax
11. 8-chloro-11-(1-((5-methylpyridin-3-yl)methyl)piperidin-4-ylidene)-6,11-dihydro-5h-benzo[5,6]cyclohepta[1,2-b]pyridine Fumarate
12. Rupatadine Fumarate (jan)
13. 1217234-48-4
14. Rupatadine Fumarate [jan]
15. (2e)-but-2-enedioic Acid; 13-chloro-2-{1-[(5-methylpyridin-3-yl)methyl]piperidin-4-ylidene}-4-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,11,13-hexaene
16. 5h-benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, (2e)-2-butenedioate (1:1)
17. Mfcd00926499
18. Unii-xj6ot32m93
19. Rupatall
20. Tamalis
21. Wystamm
22. Ralif
23. Rinialer (tn)
24. 5h-benzo(5,6)cyclohepta(1,2-b)pyridine, 8-chloro-6,11-dihydro-11-(1-((5-methyl-3-pyridinyl)methyl)-4-piperidinylidene)-, (2e)-2-butenedioate (1:1)
25. Rupafin (tn)
26. Rupatadine Fumarate- Bio-x
27. 5h-benzo(5,6)cyclohepta(1,2-b)pyridine, 6,11-dihydro-8-chloro-11-(1-((5-methyl-3-pyridinyl)methyl)-4-piperidinylidene)-, (e)-2-butenedioate (1:1)
28. 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridyl)methyl]-4-piperidylidene]-5h-benzo[5,6]cyclohepta[1,2-b]pyridine Fumarate
29. Mls006010150
30. Schembl180121
31. Schembl180512
32. Rupatadine Fumarate [mi]
33. Hms3885k05
34. Bcp05230
35. Hy-13511a
36. Rupatadine Fumarate [who-dd]
37. S3052
38. Akos005145898
39. Ac-9016
40. Ccg-269922
41. Cs-3482
42. F76r825
43. Ks-1229
44. Br164385
45. Rupatadine Fumarate [ep Monograph]
46. Smr004701267
47. Sw219889-1
48. C73520
49. D08497
50. Q-201688
51. Q27293863
52. (e)-but-2-enedioic Acid;13-chloro-2-[1-[(5-methylpyridin-3-yl)methyl]piperidin-4-ylidene]-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaene
| Molecular Weight | 532.0 g/mol |
|---|---|
| Molecular Formula | C30H30ClN3O4 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 4 |
| Exact Mass | 531.1924841 g/mol |
| Monoisotopic Mass | 531.1924841 g/mol |
| Topological Polar Surface Area | 104 Ų |
| Heavy Atom Count | 38 |
| Formal Charge | 0 |
| Complexity | 728 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Treatment of allergic rhinitis, Treatment of chronic idiopathic urticaria
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
69
PharmaCompass offers a list of Rupatadine Fumarate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Rupatadine Fumarate manufacturer or Rupatadine Fumarate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Rupatadine Fumarate manufacturer or Rupatadine Fumarate supplier.
PharmaCompass also assists you with knowing the Rupatadine Fumarate API Price utilized in the formulation of products. Rupatadine Fumarate API Price is not always fixed or binding as the Rupatadine Fumarate Price is obtained through a variety of data sources. The Rupatadine Fumarate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Rupafin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Rupafin, including repackagers and relabelers. The FDA regulates Rupafin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Rupafin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Rupafin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Rupafin supplier is an individual or a company that provides Rupafin active pharmaceutical ingredient (API) or Rupafin finished formulations upon request. The Rupafin suppliers may include Rupafin API manufacturers, exporters, distributors and traders.
click here to find a list of Rupafin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Rupafin DMF (Drug Master File) is a document detailing the whole manufacturing process of Rupafin active pharmaceutical ingredient (API) in detail. Different forms of Rupafin DMFs exist exist since differing nations have different regulations, such as Rupafin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Rupafin DMF submitted to regulatory agencies in the US is known as a USDMF. Rupafin USDMF includes data on Rupafin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Rupafin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Rupafin suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Rupafin Drug Master File in Japan (Rupafin JDMF) empowers Rupafin API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Rupafin JDMF during the approval evaluation for pharmaceutical products. At the time of Rupafin JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Rupafin suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Rupafin Drug Master File in Korea (Rupafin KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Rupafin. The MFDS reviews the Rupafin KDMF as part of the drug registration process and uses the information provided in the Rupafin KDMF to evaluate the safety and efficacy of the drug.
After submitting a Rupafin KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Rupafin API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Rupafin suppliers with KDMF on PharmaCompass.
A Rupafin CEP of the European Pharmacopoeia monograph is often referred to as a Rupafin Certificate of Suitability (COS). The purpose of a Rupafin CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Rupafin EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Rupafin to their clients by showing that a Rupafin CEP has been issued for it. The manufacturer submits a Rupafin CEP (COS) as part of the market authorization procedure, and it takes on the role of a Rupafin CEP holder for the record. Additionally, the data presented in the Rupafin CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Rupafin DMF.
A Rupafin CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Rupafin CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Rupafin suppliers with CEP (COS) on PharmaCompass.
A Rupafin written confirmation (Rupafin WC) is an official document issued by a regulatory agency to a Rupafin manufacturer, verifying that the manufacturing facility of a Rupafin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Rupafin APIs or Rupafin finished pharmaceutical products to another nation, regulatory agencies frequently require a Rupafin WC (written confirmation) as part of the regulatory process.
click here to find a list of Rupafin suppliers with Written Confirmation (WC) on PharmaCompass.
Rupafin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Rupafin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Rupafin GMP manufacturer or Rupafin GMP API supplier for your needs.
A Rupafin CoA (Certificate of Analysis) is a formal document that attests to Rupafin's compliance with Rupafin specifications and serves as a tool for batch-level quality control.
Rupafin CoA mostly includes findings from lab analyses of a specific batch. For each Rupafin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Rupafin may be tested according to a variety of international standards, such as European Pharmacopoeia (Rupafin EP), Rupafin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Rupafin USP).
